Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg, Henrik Møller



Similar documents
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre

S The Difference Between Predictive Modeling and Regression Patricia B. Cerrito, University of Louisville, Louisville, KY

Using Objective Measures to Facilitate Rehabilitation Referral

Your Guide to Express Critical Illness Insurance Definitions

CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS

Progressive Care Insurance for life A NEW TYPE OF INSURANCE

There may be up to 5 to 6 million cases of. Treatment Costs of Community- Acquired Pneumonia in an Employed Population*

Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry

Limited Pay Policy (L-222B) - Underwriting Guidelines

How To Pay For Critical Illness Insurance From The Ihc Group

Patient clinical characteristics usually are measured and

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

Statistical Report on Health

Cardiac Rehabilitation: Strategies Approaching 2020

NHS outcomes framework and CCG outcomes indicators: Data availability table

Adult Health Nursing

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes. Dr Paul Beckett Royal Derby Hospital

Quantifying Life expectancy in people with Type 2 diabetes

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

Life Living Assurance Customer guide LIVING ASSURANCE. TotalCareMax Customer guide. Life. Take charge. sovereign.co.nz

CRITICAL SKILLS FOR OPTIMUM PATIENT CARE: Care Coordination and Health Literacy

Aalborg Universitet. Published in: Arthritis. DOI (link to publication from Publisher): /2015/ Publication date: 2015

Coding. Future of Hospice. and the. An educational resource presented by

SECTION 4 COSTS FOR INPATIENT HOSPITAL STAYS HIGHLIGHTS

CERTIFICATE TERMS AND CONDITIONS

Critical Illness Insurance

Covers 60 major critical illnesses. Covers 11 minor critical illnesses. ManuMulti Care

Medicare Advantage Risk Adjustment Data Validation CMS-HCC Pilot Study. Report to Medicare Advantage Organizations

Critical Illness Supplemental Insurance

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal

All Patient Refined DRGs (APR-DRGs) An Overview. Presented by Treo Solutions

Multimorbidity in patients with type 2 diabetes mellitus in the Basque Country (Spain)

The Timber. Critical Illness Insurance Plans. Safeguard You and Your Family with

PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Amylase and Lipase Tests

Term Critical Illness Insurance

Medical Surgical Nursing (Elsevier)

This profile provides statistics on resident life expectancy (LE) data for Lambeth.

Recruiting now. Could you help by joining this study?

ECG may be indicated for patients with cardiovascular risk factors

Qualifying Events. 100% Benefit. 25% Benefit

PCHC FACTS ABOUT HEALTH CONDITIONS AND MOOD DIFFICULTIES

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Critical Illness Insurance. Simplified Second Chance 6 covered illnesses and surgeries

Radiotherapy in locally advanced & metastatic NSC lung cancer

why? 75 percent The percentage of healthy individuals over age 40 who will become critically ill at some time in the future. 3

co-sponsored by the Health & Physical Education Department, the Health Services Office, and the Student Development Center

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:

Malmö Preventive Project. Cardiovascular Endpoints

Cardiovascular Endpoints

Malmö Preventive Project. Cardiovascular Endpoints

Frequently Asked Questions

Test Your Breast Cancer Knowledge

Cardiovascular Endpoints

Long term care coding issues for ICD-10-CM

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease

Overview. Geriatric Overview. Chapter 26. Geriatrics 9/11/2012

Evidence-Informed Recommendations in Rehabilitation for Older Adults Aging with HIV: A Knowledge Synthesis

Risk Adjustment Coding/Documentation Checklist

LIMITED BENEFIT HEALTH COVERAGE FOR SPECIFIED CRITICAL ILLNESS. OUTLINE OF COVERAGE (Applicable to Policy Form CI-1.0-NC)

Critical Illness Coverage with Refund of Premium on Death

Correspondence should be addressed to Catherine E. Muehlenbein,

Risks of Testosterone?? Symptoms and Signs Suggestive of Hypogonadism

Advanced Basal Cell Carcinoma in a Large Veteran Population

Employee Critical Illness Option

Patient comorbidity must be measured in health services

Service delivery interventions

The Independent Order Of Foresters ( Foresters ) Critical Illness Rider (Accelerated Death Benefit) Disclosure at the Time of Application

Male. Female. Death rates from lung cancer in USA

Home Health Care ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Home Health Care and Top 20 codes

NC General Statutes - Chapter 130A Article 7 1

ACUTE MYELOID LEUKEMIA (AML),

Risk Adjustment Factor (RAF) RADV June 1 st 2016

Public Health Annual Report Statistical Compendium

Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK

Diseases and injury 131

Critical Illness Direct

A912: Kidney, Renal cell carcinoma

Irish Wolfhound Pedigree Breed Health Survey

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Clinical Governance Development Committee October 2007 Dr Foster RTM Alerts Progress Report

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

THE THINGs You were meant to. BENEFITS To HELP you. Cigna Supplemental Solutions Insured by Loyal American Life Insurance Company

Association of Inpatient vs Outpatient Onset of ST-Elevation Myocardial Infarction With Treatment and Clinical Outcomes

Key Health Areas Mapped to Out of Hospital Programme Areas

Achieving Quality and Value in Chronic Care Management

Underwriting and Rate Information

GRASP-AF Coming to a PCT near you.

SAMPLE. Protection Series Cancer and Heart Attack or Stroke Insurance Plans. Texas. Security solutions. For peace of mind protection.

Leukemias and Lymphomas: A primer

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer

Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care Methodology Contents

Aflac Lump Sum Critical Illness

Long Term Outcomes of Restorative Home Care

Protection Series SM Cancer and Heart Attack or Stroke Supplemental Insurance

Description of the OECD Health Care Quality Indicators as well as indicator-specific information

Transcription:

The effect of different comorbidity groups on the survival of patients with non-small cell lung cancer Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg, Henrik Møller

Comorbidity comorbidity is the presence of one or more diseases in addition to a primary disease Comorbidity index the Cumulative Illness Rating Scale (CIRS) the Index of Co-Existent Disease (ICED) the Kaplan Feinstein Classification (KFC) the Charlson Comorbidity Index (CCI)

Charlson Index ShortName Name Weight AMI Acute Myocardial Infarction 1 HF Congestive Heart Failure 1 VASC Peripheral Vascular Disease 1 CVD Cerebrovascular Disease 1 DEMENS Dementia 1 COL Chronic Obstructive Pulmonary Disease CONNECT Connective Tissue Disease 1 ULCUS Peptic Ulcer Disease 1 LIVER_MILD Mild liver disease 1 DM_UNCOMP DM without complications 1 HEMIPLEG Hemiplegia 2 KIDNEY Mod-Severe Renal Disease 2 DM_COMP DM with complications 2 CA_SOLID Any tumor (Danish: Solide kræftformer) LEUC Leukemia 2 LYMPH Lymphoma 2 LIVER_SEVERE Mod-Severe Liver Disease 3 CA_METAST Metastatic solid tumor (Dansk: Metastaserende cancer) AIDS AIDS 6 1 2 6

Comorbidity groups ShortName Name Group AMI Acute Myocardial Infarction cardiovascular disorders HF Congestive Heart Failure cardiovascular disorders VASC Peripheral Vascular Disease peripheral vascular disorders including cerebrovascular disorders CVD Cerebrovascular Disease peripheral vascular disorders including cerebrovascular disorders HEMIPLEG Hemiplegia peripheral vascular disorders including cerebrovascular disorders LEUC Leukemia Cancer LYMPH Lymphoma Cancer LIVER_SEVERE Mod-Severe Liver Disease Cancer CA_METAST Metastatic solid tumour Cancer CA_SOLID Any tumor Cancer COL Chronic Obstructive Pulmonary Disease Other complicated diseases CONNECT Connective Tissue Disease Other complicated diseases KIDNEY Mod-Severe Renal Disease Other complicated diseases DM_COMP DM with complications Other complicated diseases DEMENS Dementia Other complicated diseases AIDS AIDS Other complicated diseases ULCUS Peptic Ulcer Disease Other uncomplicated condition LIVER MILD Mild liver disease Other uncomplicated condition DM UNCOMP DM without complications Other uncomplicated condition

Study population The analysis is based on lung cancer patients who have a diagnosed NSCLC in 2009-2011 and are registered in DLCR We included information on comorbidity for each patient up to 10 years before lung cancer diagnosis, using the Danish National Patient Register

Methods There will be performed six separate analyses, one for each disease group and one for multiple comorbidity control: no records in CRS in 10 years case: at least one record from only one disease group in CRS in 10 years

Number of patients with comorbidity in one disease group group Group name Number 0 None 4,872 1 Uncomplicated disorders 329 2 Cardio-vascular disorders 285 3 peripheral vascular disorders including cerebrovascular disorders 4 Other complicated diseases 1,190 5 Cancer 701 6 Multiple 2,227 774

Kaplan-Meier survivor functions 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0 500 1000 1500 days 0 500 1000 1500 days 0 500 1000 1500 days none uncomplicated none complicated none cardiovascular 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0 500 1000 1500 days 0 500 1000 1500 analysis time 0 500 1000 1500 days none peripheral vascular none cancer none multiple

Cox regression analysis HR 95% CI Uncomplicated condition 1.19 1.04 ; 1.36 Other complicated diseases 1.24 1.15 ; 1.35 Cardio-vascular disorders 1.30 1.13 ; 1.49 Peripheral vascular disorders including cerebrovascular disorders 1.09 1.00 ; 1.20 Cancer 0.92 0.84 ; 1.03 Multiple disorders 1.26 1.19 ; 1.35 adjusted by age, sex, stage and resection

symptoms GP referral to the hospital diagnostic process treatment death Impact of comorbidity time impact quality impact

What do we have? Unfortunately, we do not know when the first symptoms appear We have no information from the GP From the time of referral to the hospital for all lung cancer patients all clinical relevant information is reported to the DLCR

referral to the hospital diagnostic process treatment death Impact of comorbidy time impact quality impact

age, sex clinical stage resection true stage mortality comorbidity

Models Staging model: clinical stage f ( true stage, age, sex, comorbidity ) Resection model: Survival model: mortality resection g( clinical stage, age, sex, comorbidity) h( true stage, age, sex, comorbidity, resection)

Estimation methods Maximum likelihood STATA, SAS, SPCC MCMC WinBugs ( gives the possibility to estimate three models at the same time)

Results of estimation using MCMC Staging model Resection model Survival model Uncomplicated condition 0.97 (0.65; 1.40) 1.00 (0.66; 1.58) 1.08 (0.95; 1.24) Other complicated 1.13 (0.87; 1.46) 0.57 (0.44; 0.74) 1.17 (1.07; 1.28) diseases Cardio-vascular disorders 0.86 (0.57; 1.28) 0.54 ( 0.34; 0.86) 1.32 (1.14; 1.52) Peripheral vascular and cerebrovascular disorders 1.00 (0.69; 1,49) 0.94 (0.64; 1.46) 1.07 (0.92; 1.22) Cancer 1.13 (0.83; 1.49) 0.78 (0.56; 1.07) 0.95 (0.85; 1.05)

Conclusions We could not find an effect of any comorbidity groups on staging process We found that the presence of some burdensome diseases or cardio-vascular disorders have a negative effect on the chance of resection The presence of some burdensome diseases or cardio-vascular disorders has a negative effect on survival

Future Research a similar analysis will be performed on English patients data